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Hypothesis: advancing clinical care in type 2 diabetes through ‘Personalized systolic 
blood pressure target ranges’? 
Intervention thresholds may be too high for some people 
Cardiovascular mortality remains the leading cause of death in type 2 diabetes (T2D). After 
publication of the results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
blood pressure lowering trial,1 several guideline committees raised target systolic blood 
pressure (sBP) thresholds for most T2D patients from 130 mmHg to 140 mmHg.2 This is 
controversial because some, perhaps many, patients might benefit from lower sBP levels.1,3 
Hypothesis 
In T2D, ‘personalized sBP target ranges’ will improve CVD outcomes and reduce adverse 
events compared to using generalized sBP intervention thresholds. 
‘Personalized’ rather than ‘generalized’ 
Some guideline committees have started to consider personalized sBP targets but this 
approach has a limited evidence base has not been widely promoted: a) the American 
Diabetes Association recommends a sBP target of <140 mmHg for ‘most patients’ but 
recognises a target of <130 mmHg may be appropriate for individuals at high risk of 
cardiovascular disease if this can be achieved without undue treatment burden;4 b) the UK’s 
National Institute for Health and Care Excellence recommends a sBP target of <140 mmHg 
for ‘most patients’ but <130 mmHg for those with kidney, eye or cerebrovascular damage.5  
In the same way that glucose targets in T2D are personalized, a ‘more stringent’ target clinic 
sBP range (115-130 mmHg) or a ‘less stringent’ range (120-140 mmHg) could be chosen 
based on the presence or absence of several factors such as: heart failure; CVD and 
microvascular complications; CVD risk; patient attitudes to stoke prevention and 
polypharmacy; postural hypotension; falls risk; cognitive impairment; presence of 
resources/support systems (figure). Although these factors are based largely on clinical 
experience, they might be a useful starting point pending data-driven improvements.4  
‘Ranges’ rather than ‘thresholds’ are designed to encourage physicians to reduce 
antihypertensive therapy at low sBPs’ 
Use of target sBP ranges rather than thresholds are justified because: a) over-treatment of 
sBP can lead to myocardial ischemia, syncope and serious injury;1 b) clinical staff can stop 
thinking about the risks of over-treatment when simply treating to below a sBP threshold; c) 
experienced clinicians routinely reduce antihypertensive therapy when sBP levels are ‘too 
low’; d) in clinical practice the risks of adverse events and ‘drop outs’ could be lower than in 
the ACCORD BP trial1 because the trial did not include a protocol for reducing therapy at low 
sBP levels; and finally e) few hypertension guidelines recommend reducing therapy at low 
sBP levels (only in frail elderly patients).4,6 
Ranges informed by ACCORD trial data 
The ACCORD trial was the largest to test the hypothesis that intensive sBP lowering 
reduces cardiovascular risk in T2D.1 Intensive sBP lowering reduced the risk for stroke and, 
in what was probably an underpowered trial, there was a suggestion of a reduction in the risk 
for the primary outcome (HR (95% CI): 0.88 (0.73-1.06)).  
If we accept that ACCORD provides the most relevant data, then the method of sBP 
measurement in this trial should be considered when setting clinical targets. In this trial, sBP 
values were the average of three automated measurements taken after 5 minutes rest.1 
Target ranges suggested here assume that a single sBP measured in a clinical setting, 
without 5 minutes rest and with clinic personnel in the room, will be ~10 mmHg higher than 
in ACCORD.7 
Therefore, the upper boundary (130 mmHg) of the ‘more stringent’ sBP range corresponds 
to the intensive sBP ACCORD target (120 mmHg) and the lower boundary (115 mmHg) is 
the ‘rescue’ sBP below which physicians are encouraged to reduce antihypertensive therapy 
(Figure).  
The upper boundary of the ‘less stringent’ sBP range (140 mmHg), corresponds to the sBP 
threshold adopted by most clinical guidelines2 and the lower reading (120 mmHg) is the 
‘rescue’ sBP in these individuals (Figure).  
Exceptional cases: very frail elderly people 
Whilst the suggested personalized target ranges might be appropriate for the majority of 
individuals, there maybe some very frail elderly individuals who are more appropriately 
treated to within a higher sBP target range of 130-160 mmHg - as suggested by a recent 
position statement by the American Diabetes Association4 and a paper from European 
Society of Hypertension–European Union Geriatric Medicine Society.6 As in the preceding 
text, these recommendations are based on expert opinion; no trail data is available to guide 
management in these people. 
Blood pressure measurement methods 
We set our target sBP ranges based on single sBP measured without 5 minutes rest 
because this is how BP is measured in most clinic settings currently. Use of a 5-minutes rest 
period prior to taking 3 BP measurements could enhance patient care by improving the 
accuracy, precision and repeatability of BP readings. There could be clinical advantages in 
aligning routine BP measurements to those used in trials, but this needs further study (see 
Future work below). 
Adverse impact on mortality – a misleading signal from ACCORD? 
The ACCORD trial suggested a potential to increase mortality through intensive sBP 
lowering (total mortality: HR (95%CI: 1.07 (0.85–1.35); CVD mortality: 1.06 (0.74–1.52)).1,8 
However, these non-significant trends were observed only in the subgroup treated to an 
aggressive HbA1c target (<6%).3 Since this HbA1c target is rarely adopted in clinical 
practice, any potential to increase mortality through intensive sBP lowering could be 
minimised - especially if low sBP levels prompt a reduction in antihypertensive medication as 
suggested here. Severe hypoglycaemia in the setting of severe hypotension (reducing 
coronary perfusion) could be harmful in T2D especially in the presence of high coronary 
disease burden, autonomic neuropathy and arterial stiffness. In keeping with this notion, 
recent post hoc data shows that intensive compared to standard sBP lowering in ACCORD 
participants at high CVD risk in the standard glucose control arm, was associated with lower 
risks for CVD outcomes: e.g. HR for CVD death, nonfatal MI or nonfatal stroke: 0.69; 95% CI 
0.51–0.93.9 
Future work 
Future research including clinical trials could usefully: a) test the stated hypothesis (see 
below); b) define optimal personalized BP ranges for individuals depending on the presence 
of relevant risk factors (outcomes being CVD risk reduction and treatment-related adverse 
events);10 c) if personalized BP ranges are beneficial, incorporate these data in clinical 
decision support systems aiming to minimise clinical inertia; d) define optimal personalized 
BP ranges based on automated office BP, home BP and 24-hour ambulatory BP levels; e) 
standardize and align blood pressure measurement methods in trials and clinical practice. 
The stated hypothesis could be tested in a cluster-randomized trial in which patients receive 
one of three interventions: a) usual care; b) a personalized sBP target level; or c) a 
personalized sBP target range. 
Conclusions 
We hypothesise that personalized target blood pressure should often be lower than currently 
achieved and that adoption of BP ranges could reduce CVD risk while minimising adverse 






Using this approach, physicians can decide on the most appropriate sBP target range 
depending on the presence or absence of relevant risk factors (figure). 
  
For example, a highly motivated and compliant patient with heart failure and renal 
impairment who has a positive attitude to polypharmacy and no adverse factors might be 
better treated to the ‘more stringent’ sBP target range (115-130 mmHg). However, a less 
motivated patient with heart failure and renal impairment with a history of falls and postural 
hypotension would be more appropriately managed to the ‘less stringent’ sBP target range 
(120-140 mmHg).  
Asking patients about postural dizziness and measuring sBP lying and standing will help to 
identify people with postural hypotension. If a patient reports symptoms of postural 
hypotension or if the sBP levels fall below the lower threshold of the stated ranges then the 
clinician is encouraged to consider reducing antihypertensive therapy.  
The upper boundary for stringent sBP range is based on ACCORD trial data adjusted for 
sBP measurement methodology. The upper boundary of the ‘less stringent’ sBP range (140 
mmHg) corresponds to the sBP threshold adopted by most clinical guidelines.2 The lower 
boundaries for the sBP ranges, and the factors influencing decision-making, are based on 
clinical experience.  
The suggested algorithm would be inappropriate a very old and frail individuals (see 
text).Both upper and lower boundaries for the ranges and the factors influencing the 
stringency of sBP targets ranges could be modified through the acquisition of trial data. 
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